PharmAust (ASX:PAA), a clinical-stage oncology company, has appointed eminent US-based veterinary cancer specialist Dr Barbara Kitchell to its Veterinary Advisory Board.
Dr Kitchell is director of Residency Training for Veterinary Centers of America and staff oncologist at the VCA Veterinary Care Animal Hospital and Referral Center in New Mexico.
Previously, she was professor and director of the Center for Comparative Oncology at Michigan State University. She has also held academic and clinical positions specialising in comparative oncology at other institutions including Stanford University, University of Illinois and University of California, Davis.
"Dr Kitchell is recognised as a key opinion leader in comparative oncology, clinical trials and drug development," said the company.
"Dr Kitchell has successfully led more than 27 clinical studies and is a member of various national and international veterinary cancer organisations. She is the author of over 100 scientific publications, abstracts, proceedings, book chapters and handbooks in her field of veterinary and comparative oncology."
"As a comparative oncologist I am very pleased to join the PharmAust advisory board to support the development of drugs that will potentially help both animals and humans," said Dr Kitchell.
Dr Frimberger, the chair of PharmAust’s Vet Advisory Committee, said, “Dr Kitchell brings a wealth of expertise in general veterinary oncology and new drug development and shares our interest in mTOR inhibitors. With everything that she brings to this team, I can’t wait to get to work!”
“We are delighted to have attracted another world leader in the field of comparative oncology to our highly credentialed advisory team. Dr Kitchell’s expertise and networks will be invaluable as we look to accelerate clinical development of our lead candidate in Australia and overseas,” added CEO Dr Richard Hopkins.